Analysis of The QT Interval in Clinical Trials

Abstract

We explore adaptive (data-driven) approaches in the analysis of clinical QT data in order to find scientifically-sound solutions for correcting the QT interval for heart rate and for analysis of extreme QT measurements. We demonstrate that predefined QT correction formulas (eg, Bazett and Fridericia formulas) are unreliable when the investigational drug induces heart rate changes. Further, simple data-driven approaches (eg, QT correction formulas derived from baseline data in clinical trials) lead to a substantial inflation of the false positive rate. We discuss a QT interval analysis framework based on repeated-measures models that account for correlation among serial ECG measurements collected on the same subject and drug-induced heart rate changes. We also assess the performance of reference ranges for QT interval currently used in clinical trials.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Algra A, Tijssen IG, Roelandt JR, Pool I, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation. 1991;83:1888–1894.

    CAS  Article  Google Scholar 

  2. 2.

    Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for Torsades de Pointes associated with cardiovascular drugs. JAMA. 1993;270:2590–2597.

    CAS  Article  Google Scholar 

  3. 3.

    Malik M. Problems of heart rate correction in the assessment of drug-induced QT interval prolongation. J Cardiovascular Electrophysiology. 2001; 12.

    Google Scholar 

  4. 4.

    Bazett HC. An analysis of time relations of electrocardiograms. Heart. 1920;7:353–367.

    Google Scholar 

  5. 5.

    Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Medica Scandinavica. 1920;64: 469–486.

  6. 6.

    Fenichel R, Koerner J. Development of drugs that alter ventricular repolarization. 1999. http://www.fenichel.net.

    Google Scholar 

  7. 7.

    Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurements in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiology. 1991;67:774–776.

    CAS  Article  Google Scholar 

  8. 8.

    Morganroth J, Brown AM, Critz S, Crumb WJ, Kunze DL, Lacerda AE, Lopez H. Variability in the QTc interval: impact on defining drug effect and low-frequency cardiac events. Am J Cardiology. 1993;64:26B–31B.

    Article  Google Scholar 

  9. 9.

    Lande G, Funck-Brentano C, Ghadanfar M, Escande D. Steady-state versus nonsteady-state QT-RR relationships in 24-hour Holter recordings. Pacing Clinical Electrophysiology. 2000;23:293–302.

    CAS  Article  Google Scholar 

  10. 10.

    Spence S, Soper K, Hoe CM, Coleman I. The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. Toxico-logical Sciences. 1998;45:247–258.

    CAS  Article  Google Scholar 

  11. 11.

    Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. European Heart J. 2000;21:1216–1231.

    CAS  Google Scholar 

  12. 12.

    Committee for Proprietary Medicinal Products. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London, UK: Committee for Proprietary Medicinal Products; December 17, 1997.

    Google Scholar 

  13. 13.

    Health Canada. Therapeutic Products Programme. Assessment of the QT prolongation potential of non-cardiovascular drugs. Ottawa, Canada: Health Canada; March 15, 2001.

    Google Scholar 

  14. 14.

    Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiology. 1992;70:797–801.

    CAS  Article  Google Scholar 

  15. 15.

    Hodges M, Salemo D, Erlien D. Bazett’s QT correction reviewed: evidence that a linear correction for heart rate is better. J Am College Cardiology. 1983;64:694.

  16. 16.

    Kawataki M, Kashima T, Toda H, Tanaka H. Relation between QT interval and heart rate applications and limitations of Bazett’s formula. J Elecrocardiology. 1984;17:371–375.

    CAS  Article  Google Scholar 

  17. 17.

    Malik M. If Dr. Bazett had had a computer.... Pacing Clinical Electrophysiology. 1996;19:1635–1639.

    CAS  Article  Google Scholar 

  18. 18.

    Vandenhende F. Heart rate specific reference ranges for QT interval in beagle dogs. Drug InfJ. 2001;64.

  19. 19.

    FDA Psychopharmacological Drugs Advisory Committee 15 February 2001. Briefing Document for Ziprasidone Mesylate for intramuscular injection. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2_01_pfizer.pdf.

  20. 20.

    Molnar J, Weiss J, Zhang F, Rosenthal JE. Evaluation of five QT correction formulas using a software-assisted method of continuous QT measurement from 24-hour Holter recordings. Am J. Cardiology. 1996;78:920–926.

    CAS  Article  Google Scholar 

  21. 21.

    Chuang-Stein C. Safety analysis in controlled clinical trials. Drug Inf J. 1998; 32, 1363S–1372S.

    Article  Google Scholar 

  22. 22.

    Moss AJ, Robinson JL. The long-QT syndrome: genetic considerations. Trends Cardiovascular Med. 1992;2:81–83.

    CAS  Article  Google Scholar 

  23. 23.

    MacFarlane PW, Lawie TDV. Comprehensive Electrocardiography: Theory and Practice in Health and Disease. Oxford: Pergamon Press; 1989.

    Google Scholar 

  24. 24.

    FDA Psychopharmacological Drugs Advisory Committee 19 July 2000. Briefing Document for Zeldox capsules (Ziprasidone HC1). http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619bla.pdf.

  25. 25.

    FDA Anti-Infective Drugs Advisory Committee April 26, 2001. Briefing Document for Ketek (telithromycin). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3746b_02_FDA.pdf.

  26. 26.

    De Bruyne MC, Hoes AW, Kors JA, Dekker JM, Hofman A, van Bemmel JH, Grobbee DE. Prolonged QT interval: a tricky diagnosis? Am J Cardiology. 1997;80:1300–1304.

    Article  Google Scholar 

  27. 27.

    Nickens DJ. Using tolerance limits to evaluate laboratory data. Drug Inf J. 1998;32:261–269.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Alex Dmitrienko PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dmitrienko, A., Smith, B.P. Analysis of The QT Interval in Clinical Trials. Ther Innov Regul Sci 36, 269–279 (2002). https://doi.org/10.1177/009286150203600205

Download citation

Key Words

  • ECG
  • Cardiac repolarization
  • QT interval
  • QT correction for heart rate
  • Reference ranges